8.35 (-%)
As of Nov 21, 2024
Source:
We are a biopharmaceutical company developing a portfolio of novel and proprietary small molecule drugs that employ the bodys natural mechanisms to selectively degrade therapeutically-relevant proteins, so called molecular glue degraders or MGDs. We have developed a proprietary protein degradation platform, called QuEEN (an abbreviation for Quantitative and Engineered Elimination of Neosubstrates), to enable our target-centric approach to our MGD discovery and development.
Country | United States |
Headquarters | boston, massachusetts |
Phone Number | 617-949-2643 |
Industry | |
CEO | Markus Warmuth |
Website | www.monterosatx.com |